Table 1.

The antibodies that could be used to treat AIDs.

Class	Name	Type	Target	Major indication	Research stage
TNF inhibitor	Infliximab	mAb	TNF-α	RA,CD,UC,AS,pasoriasis	marketed
	Etanercept	fusion protein	TNF	AS, psoriasis, juvenile idiopathic arthritis, RA	marketed
	Adalimumab	mAb	TNF	RA, AS, CD, UC, psoriasis	marketed
	Certolizumab pegol	mAb	TNF	CD, RA, AS	marketed
	Golimumab	mAb	TNF	RA, psoriatic arthritis, AS, UC	marketed
	Ozoralizumab	nanobody	TNF-α	RA	marketed
IL-6 inhibitor	Tocilizumab	mAb	IL-6R	RA, juvenile idiopathic arthritis, CD, SLE, SSc	marketed
	Sarilumab	mAb	IL-6R	RA	marketed
	Sirukumab	mAb	IL-6	RA, SLE	phase III
	Clazakizumab	mAb	IL-6	RA	phase III
	Olokizumab	mAb	IL-6	RA	phase III
	ALX-0061	nanobody	IL-6R, HAS	RA	phase II
IL-1 inhibitor	Anakinra	recombinant IL-1Ra	IL-1R	RA, NOMID	marketed
	Canakinumab	mAb	IL-1β	CAPSs, sJIA	marketed
	Rilonacept	fusion protein	IL-1β	recurrent pericarditis, CAPSs, sJIA	marketed
	Gevokizumab	mAb	IL-1β	autoinflammatory diseases	marketed
IL-17 inhibitor	Secukinumab	mAb	IL-17A	PsA, AS, psoriasis, PSO, axSpA	marketed
	Ixekizumab	mAb	IL-17A or IL-17A/F	PsA, AS, psoriasis, PSO, axSpA	marketed
	Brodaluma	mAb	IL-17R	Psoriasis, PsA	marketed
	Bimekizuma	mAb	IL-17A, IL-17F	PSO, PsA, AS, axSpA	marketed
	Sonelokimab	nanobody	IL-17A/F	PsA, PSO	phase II
	Netakimab	mAb	IL-17A	PSO, AS	phase III
	Vunakizumab	mAb	IL-17A	PSO	phase II
	CNTO6785	mAb	IL-17A	RA	phase II
	COVA322	FynomAb	TNF, IL-17A	PsA	phase I
	ABT-122	mutant immunoglobulin (DVD-Ig™) molecule	TNF, IL-17A	RA, PsA	phase II
	CJM112	mAb	IL-17A	PSO	phase I
IL-12/23 inhibitor	Ustekinumab	mAb	IL-12/23 p40	CD, UC, PsA, PSO	marketed
	Guselkumab	mAb	IL-23 p19	PsA, PSO, IBD	marketed
	Tildrakizumab	mAb	IL-23 p19	PSO, PsA	marketed
	Risankizumab	mAb	IL-23	PSO, PsA, CD	marketed
	Mirikizumab	mAb	IL-23 p19	UC	marketed